U.S. Markets open in 8 hrs 25 mins

Kura Oncology Soars After Lymphoma Treatment Test Results

Rob Lenihan

climbed 6.6% to $19.71 Friday after the clinical-stage biopharmaceutical company said a phase 2 trial of its lymphoma treatment tipifarnib showed encouraging results and achieved its primary endpoint. The San Diego-based company said the results demonstrate ongoing anti-tumor activity and a manageable safety profile in advanced patients with angioimmunoblastic T-cell lymphoma (AITL) as well as non-AITL peripheral T-cell lymphoma (PTCL). "With additional follow up and new patients enrolled in the ongoing Phase 2 study, tipifarnib continues to demonstrate encouraging clinical activity in patients with relapsed or refractory PTCL who have experienced a median of three prior lines of therapy," Francine Foss, professor of medicine at the Yale Cancer Center, and a principal investigator in the trial, said in a statement.